Aporte a la rutina de la trinchera asistencial donde los conocimientos se funden con las demandas de los pacientes, sus necesidades y las esperanzas de permanecer en la gracia de la SALUD.
martes, 15 de septiembre de 2020
Enhancing Breast Cancer Therapy through Killing ‘Sleeper Cells’
AZoLifeSciences speaks to Dr. James Whittle and Professor Geoff Lindeman about their research in enhancing breast cancer therapy through killing sleeper cells.
Genetic studies covering 266,000 women have revealed 32 new sites on the genome where variations in DNA appear to alter the risks of getting breast cancer.
Using the venom from 312 honeybees and bumblebees in Perth Western Australia, Ireland and England, Dr Ciara Duffy from the Harry Perkins Institute of Medical Research and The University of Western Australia, tested the effect of the venom on the clinical subtypes of breast cancer, including triple-negative breast cancer, which has limited treatment options.
Researchers from the Garvan Institute of Medical Research have uncovered four new subtypes of cells within triple-negative breast cancer, which contain promising new therapeutic targets for the aggressive disease.
Over the years, our knowledge of diseases has improved, and several hereditary gene variants have been found that may predispose to the development of cancer.
Beginning in March, as COVID-19 cases surged in various states in the U.S., the COVID-19 Pandemic Breast Cancer Consortium released recommendations that operations for ductal carcinoma in situ (DCIS) be deferred due to the pandemic.
Two novel biomarkers have been found to correlate with improved outcomes with immunotherapy in metastatic breast cancer and may help to identify the patients most likely to benefit from this treatment, according to exploratory studies reported at the ESMO Breast Cancer Virtual Meeting 2020.
ver historia personal en: www.cerasale.com.ar [dado de baja por la Cancillería Argentina por temas políticos, propio de la censura que rige en nuestro medio]//
www.revistamedicos.com.ar //
www.quorumtuc.com.ar //
www.sectorsalud.com.ar //
www.maimonides.edu //
weblog.maimonides.edu/farmacia/archives/UM_Informe_Autoevaluacion_FyB.pdf - //
weblog.maimonides.edu/farmacia/archives/0216_Admin_FarmEcon.pdf - //
www.documentalistas.org.ar //
www.cpcesfe2.org.ar //
www.nogracias.eu //
www.estenssorome.com.ar //
www.cuautitlan.unam.mx/descargas/licenciaturas/bqd/plandestudio_bqd_ //
www.latamjpharm.org/trabajos/25/2/LAJOP_25_2_6_1_M4M6Z9746D.pdf //
www.nogracias.eu/v_juventud/informacion/informacionver.asp?cod= //
www.colfarse.com.ar //
www.proz.com/kudoz/english_to_spanish/art_literary/523942-key_factors.html - 65k - // www.llave.connmed.com.ar/portalnoticias_vernoticia.php?codigonoticia=17715 // www.frusculleda.com.ar/homepage/espanol/activities_teaching.htm // http://www.on24.com.ar/nota.aspx?idNot=36331 ||
No hay comentarios:
Publicar un comentario